{
 "query": "nirmatrelvir",
 "ingredient": "nirmatrelvir",
 "slug": "nirmatrelvir",
 "rxcui": "2587892",
 "brands": [],
 "names": [
  "nirmatrelvir"
 ],
 "classes": [],
 "alternatives": [],
 "label": {},
 "faers": {
  "total": 288,
  "serious": 260,
  "death": 11,
  "hospitalization": 214,
  "primary_suspect": 146,
  "top_reactions": [
   [
    "Drug Interaction",
    214
   ],
   [
    "Toxicity To Various Agents",
    131
   ],
   [
    "Acute Kidney Injury",
    108
   ],
   [
    "Immunosuppressant Drug Level Increased",
    51
   ],
   [
    "Covid-19",
    49
   ],
   [
    "Diarrhoea",
    24
   ],
   [
    "Off Label Use",
    23
   ],
   [
    "Vomiting",
    23
   ],
   [
    "Nausea",
    21
   ],
   [
    "Drug Level Increased",
    17
   ],
   [
    "Encephalopathy",
    17
   ],
   [
    "Hyperkalaemia",
    17
   ],
   [
    "Drug Level Above Therapeutic",
    13
   ],
   [
    "Headache",
    13
   ],
   [
    "Blood Creatinine Increased",
    12
   ]
  ],
  "by_year": {
   "2021": 1,
   "2022": 45,
   "2023": 73,
   "2024": 97,
   "2025": 58,
   "2026": 14
  },
  "by_year_primary": {
   "2021": 1,
   "2022": 29,
   "2023": 31,
   "2024": 55,
   "2025": 27,
   "2026": 3
  }
 },
 "faers_base": {
  "total": 20692304,
  "serious_share": 0.5742697381596559,
  "death_share": 0.09102355155810585
 },
 "recalls": [],
 "recall_total": 0,
 "drugsfda": {
  "applications": 0,
  "nda": 0,
  "anda": 0,
  "first_approval": "",
  "rems": false,
  "rems_last": "",
  "labeling_supplements": 0,
  "labeling_recent": 0,
  "sponsors": [],
  "unapproved": false,
  "first_approval_fmt": ""
 },
 "trials": {
  "total": 74,
  "completed": 42,
  "terminated": 6,
  "with_results": 27,
  "industry": 39,
  "phase3": 13,
  "results_share": 0.6428571428571429,
  "terminated_share": 0.08108108108108109
 },
 "pubmed": {
  "rct": 24,
  "meta": 24,
  "recent_rct": 24,
  "cochrane": [
   {
    "pmid": "38032024",
    "title": "Nirmatrelvir combined with ritonavir for preventing and treating COVID-19",
    "year": "2023"
   },
   {
    "pmid": "36126225",
    "title": "Nirmatrelvir combined with ritonavir for preventing and treating COVID-19",
    "year": "2022"
   }
  ]
 },
 "payments": {
  "year": "2024",
  "usd": 0.0,
  "records": 0,
  "by_name": [],
  "names_checked": [
   "nirmatrelvir"
  ],
  "source": "bulk-index"
 },
 "partd": null,
 "mdl": [],
 "dsc": [],
 "settlements": [],
 "prescrire": null,
 "eml": {
  "listed": false,
  "status": "",
  "name": "",
  "matched": null,
  "stewardship": []
 },
 "exposure": null,
 "scores": {
  "safety": {
   "score": 100,
   "letter": "A",
   "why": [],
   "weight": 0.35
  },
  "evidence": {
   "score": 55,
   "letter": "D",
   "why": [
    "24 randomized trials and 24 systematic reviews/meta-analyses indexed in PubMed",
    "2 independent Cochrane review(s) exist"
   ],
   "weight": 0.25
  },
  "regulatory": {
   "score": 100,
   "letter": "A",
   "why": [
    "No recalls on record since 2016"
   ],
   "weight": 0.15
  },
  "conflict": {
   "score": 100,
   "letter": "A",
   "why": [
    "Pharma paid doctors $0 tied to this drug last year: negligible",
    "Not named in any pending federal MDL"
   ],
   "weight": 0.15
  },
  "options": {
   "score": 40,
   "letter": "F",
   "why": [
    "No generic version approved: brand-only pricing (-30)",
    "No same-class alternatives found: little leverage to switch (-30)"
   ],
   "weight": 0.1
  }
 },
 "total": 83,
 "grade": "B",
 "questions": [
  "The most-reported problems in FDA's adverse event data are drug interaction, toxicity to various agents, acute kidney injury, immunosuppressant drug level increased. How would we recognize and handle those?",
  "There is no generic. Is there an older generic in the same class that works as well for my situation?",
  "What result are we expecting, by when, and what is the plan if it does not happen?",
  "If 100 people like me took this drug, how many would actually get better because of it, and how many would be harmed by it? (Doctors call these the number needed to treat and the number needed to harm.)"
 ]
}